MediciNova presented the results of the Phase 2b trial of MN-166 – ibudilast – in alcohol use disorder at the 46th Annual Research Society on Alcoholism Scientific Meeting held June 24 – 28 in Bellevue. The clinical trial was funded by the National Institute on Alcohol Abuse and Alcoholism, a component of the National Institutes of Health. The primary objective of the trial was to evaluate the effects of MN-166 vs. placebo on percent heavy drinking days over the course of a 12-week treatment period. MN-166 treatment was not superior to placebo for reducing percent heavy drinking days. Also, MN-166 treatment was not superior to placebo for the secondary endpoints.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MNOV:
- MediciNova Announces Presentation of Results from the Phase 2b Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting
- MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for Patients with Microorganism Infection in Europe
- MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 for the Treatment of Advanced NASH in Canada